Literature DB >> 22028318

Prenatal and postnatal expression of glutathione transferase ζ 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate.

Wenjun Li1, Yuan Gu, Margaret O James, Ronald N Hines, Pippa Simpson, Taimour Langaee, Peter W Stacpoole.   

Abstract

Glutathione transferase ζ 1 (GSTZ1), also known as maleylacetoacetate isomerase, catalyzes the penultimate step of tyrosine catabolism and metabolizes several α-halocarboxylic acids, including dichloroacetic acid (DCA), an investigational drug used for lactic acidosis and, recently, solid tumors. Age-related differences have been suggested in DCA pharmacotoxicology, but no information is available on GSTZ1 ontogeny in humans. Here, we investigated the cytosolic GSTZ1 developmental expression pattern and the influence of haplotype on GSTZ1 activity with DCA by using human livers from donors between 10 weeks gestation and 74 years. GSTZ1 expression was very low in fetal livers (<2 pmol of GSTZ1/mg cytosol). The expression began to increase after birth in an age-dependent manner until age 7 years. GSTZ1 was then sustained at stable, yet variable, levels (median, 20.0 pmol/mg cytosol; range, 4.8-47.3 pmol/mg cytosol) until age 74 years. GSTZ1 activity with DCA was strongly associated with haplotype and expression level. Samples homozygous or heterozygous for GSTZ1A exhibited ∼3-fold higher DCA dechlorinating activity than samples carrying other alleles at a given level of expression. The correlations (r²) between activity and expression were 0.90 and 0.68, respectively, for GSTZ1A carriers (n = 11) and noncarriers (n = 61). GSTZ1 is expressed in mitochondria in addition to cytosol. The GSTZ1A allele exhibited similar effects in the mitochondrial fraction by conferring a higher activity with DCA. In summary, we report a neonatal onset and an age-related increase in GSTZ1 protein expression during human liver development. Haplotype influenced GSTZ1 activity with DCA but not protein expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028318      PMCID: PMC3263939          DOI: 10.1124/dmd.111.041533

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

Review 1.  Scaling for size: some implications for paediatric anaesthesia dosing.

Authors:  Brian J Anderson; George H Meakin
Journal:  Paediatr Anaesth       Date:  2002-03       Impact factor: 2.556

2.  Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver.

Authors:  Zhengbo Duanmu; Amy Weckle; Sevasti B Koukouritaki; Ronald N Hines; Josie L Falany; Charles N Falany; Thomas A Kocarek; Melissa Runge-Morris
Journal:  J Pharmacol Exp Ther       Date:  2005-12-09       Impact factor: 4.030

3.  Limit of blank, limit of detection and limit of quantitation.

Authors:  David A Armbruster; Terry Pry
Journal:  Clin Biochem Rev       Date:  2008-08

4.  Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.

Authors:  Sevasti B Koukouritaki; Pippa Simpson; Catherine K Yeung; Allan E Rettie; Ronald N Hines
Journal:  Pediatr Res       Date:  2002-02       Impact factor: 3.756

5.  The development expression of alpha-, mu- and pi-class glutathione S-transferases in human liver.

Authors:  R C Strange; A F Howie; R Hume; B Matharoo; J Bell; C Hiley; P Jones; G J Beckett
Journal:  Biochim Biophys Acta       Date:  1989-12-08

6.  Glutathione S-transferases and thiol concentrations in embryonic and early fetal tissues.

Authors:  M T Raijmakers; E A Steegers; W H Peters
Journal:  Hum Reprod       Date:  2001-11       Impact factor: 6.918

7.  Glutathione transferase zeta catalyses the oxygenation of the carcinogen dichloroacetic acid to glyoxylic acid.

Authors:  Z Tong; P G Board; M W Anders
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

8.  Human hepatic CYP2E1 expression during development.

Authors:  Elizabeth K Johnsrud; Sevasti B Koukouritaki; Karthika Divakaran; Laura L Brunengraber; Ronald N Hines; D Gail McCarver
Journal:  J Pharmacol Exp Ther       Date:  2003-10       Impact factor: 4.030

9.  Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.

Authors:  Albert L Shroads; Xu Guo; Vaishali Dixit; Hui-Ping Liu; Margaret O James; Peter W Stacpoole
Journal:  J Pharmacol Exp Ther       Date:  2007-12-20       Impact factor: 4.030

10.  Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal liver and primary carcinomas.

Authors:  T P Mulder; H M Roelofs; W H Peters; M J Wagenmans; C F Sier; H W Verspaget
Journal:  Carcinogenesis       Date:  1994-10       Impact factor: 4.944

View more
  12 in total

1.  Age-Related Changes in miRNA Expression Influence GSTZ1 and Other Drug Metabolizing Enzymes.

Authors:  Stephan C Jahn; Lauren A Gay; Claire J Weaver; Rolf Renne; Taimour Y Langaee; Peter W Stacpoole; Margaret O James
Journal:  Drug Metab Dispos       Date:  2020-05-01       Impact factor: 3.922

2.  Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1.

Authors:  Guo Zhong; Margaret O James; Marci G Smeltz; Stephan C Jahn; Taimour Langaee; Pippa Simpson; Peter W Stacpoole
Journal:  Drug Metab Dispos       Date:  2018-05-31       Impact factor: 3.922

3.  Regulation of dichloroacetate biotransformation in rat liver and extrahepatic tissues by GSTZ1 expression and chloride concentration.

Authors:  Stephan C Jahn; Marci G Smeltz; Zhiwei Hu; Laura Rowland-Faux; Guo Zhong; Ryan J Lorenzo; Katherine V Cisneros; Peter W Stacpoole; Margaret O James
Journal:  Biochem Pharmacol       Date:  2018-04-05       Impact factor: 5.858

Review 4.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.

Authors:  Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole
Journal:  Pharmacol Ther       Date:  2016-10-19       Impact factor: 12.310

5.  Chloride and other anions inhibit dichloroacetate-induced inactivation of human liver GSTZ1 in a haplotype-dependent manner.

Authors:  Guo Zhong; Wenjun Li; Yuan Gu; Taimour Langaee; Peter W Stacpoole; Margaret O James
Journal:  Chem Biol Interact       Date:  2014-03-13       Impact factor: 5.192

6.  Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children.

Authors:  Naveen Mangal; Margaret O James; Peter W Stacpoole; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2017-09-15       Impact factor: 3.126

7.  The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.

Authors:  Taimour Y Langaee; Guo Zhong; Wenjun Li; Issam Hamadeh; Mohamed Hassan M Solayman; Caitrin W McDonough; Peter W Stacpoole; Margaret O James
Journal:  Pharmacogenet Genomics       Date:  2015-05       Impact factor: 2.089

8.  A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Authors:  Matthew K Matlock; Abhik Tambe; Jack Elliott-Higgins; Ronald N Hines; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2019-07-29       Impact factor: 3.739

9.  Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats.

Authors:  Edwin J Squirewell; Marci G Smeltz; Laura Rowland-Faux; Lloyd P Horne; Peter W Stacpoole; Margaret O James
Journal:  Drug Metab Dispos       Date:  2020-09-01       Impact factor: 3.922

Review 10.  Pharmacogenetic considerations with dichloroacetate dosing.

Authors:  Margaret O James; Peter W Stacpoole
Journal:  Pharmacogenomics       Date:  2016-05-04       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.